Cystic Fibrosis Trust, London, UK.
Monash University, Melbourne, Australia.
J Cyst Fibros. 2020 May;19(3):355-358. doi: 10.1016/j.jcf.2020.04.012. Epub 2020 Apr 25.
Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis.
Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised.
40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted.
This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.
关于新型冠状病毒（SARS-CoV-2）对囊性纤维化（CF）患者的临床影响，信息有限。我们的目的是描述囊性纤维化患者的 SARS-CoV-2 感染情况。
通过标准化模板报告了每个参与国家向其国家 CF 登记处提交的匿名数据，然后对数据进行了整理和总结。
8 个国家报告了 40 例病例。在这 40 例病例中，31 例（78%）在出现时出现 SARS-CoV-2 症状，24 例（60%）有发热。70%的患者已康复，30%的患者在报告时仍未解决，目前没有死亡病例报告。
本早期报告显示，在这一异质性 CF 队列中，SARS-CoV-2 的恢复情况良好。疾病过程似乎与普通人群没有区别，但目前的数字太小，无法得出明确的结论，CF 患者仍应继续严格遵循公共卫生建议，以保护自己免受感染。
